Syrma Johari MedTech Limited (SJML), a leading medical device design and manufacturing partner, successfully attended LSI Asia 2026, held from Jun 30 – Jul 2, 2026 in Singapore.
LSI Asia 2026 Emerging MedTech Summit, one of Asia’s premier gatherings brings together medtech innovators, investors, clinicians, and strategic partners from across the region. The event reinforced SJML’s continued commitment to advancing medical technology innovation through integrated, end-to-end CDMO and QARA solutions.
Connecting Across the Global MedTech Value Chain
At LSI Asia 2026, the SJML team engaged with a diverse cross-section of the medtech community from early-stage startups and growth-stage companies to established OEMs, investors, and clinicians. These conversations spanned the full spectrum of the industry, offering a valuable platform to exchange perspectives on emerging medical technologies, commercialization strategies, and the evolving dynamics shaping the global medtech landscape.
Witnessing APAC’s Growing MedTech Momentum
A key takeaway from the summit was the accelerating momentum within the APAC medtech ecosystem. Increasing innovation, deeper collaboration, and rising investment activity are together driving healthcare advancement across the region, positioning Asia-Pacific as an increasingly influential hub for medical device development and commercialization.
Driving Conversations on Development, Manufacturing, and Market Access
Throughout the summit, SJML took part in discussions centered on product development, manufacturing scale-up, regulatory pathways, and global market access. These conversations underscored a shared industry recognition: bringing a medical device from concept to market requires integrated partnerships that connect design, engineering, manufacturing, and regulatory expertise from day one.
Supporting Innovators at Every Stage
SJML also explored opportunities to support companies across the full innovation continuum, from startups and growth-stage businesses to established OEMs with their end-to-end CDMO, QARA, and technology capabilities. These interactions reflect SJML’s broader mission of helping partners navigate the complex journey from concept to commercially successful, globally accessible medical technologies.
Building Long-Term Strategic Relationships
Beyond individual conversations, LSI Asia 2026 provided an opportunity for SJML to strengthen relationships with stakeholders spanning the entire medtech value chain, laying the groundwork for long-term strategic collaborations in the years ahead.
Reaffirming SJML’s Commitment to MedTech Innovation
SJML’s participation at LSI Asia 2026 reaffirmed the company’s ongoing commitment to enabling MedTech innovators worldwide in transforming promising ideas into commercially successful, globally accessible medical technologies backed by decades of design-led engineering, manufacturing, and regulatory expertise.
Learn more about SJML’s participation at the LSI Asia 2026 event on our LinkedIn page!
